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Abstract
 
Human T cell leukemia virus type I (HTLV-I) is a persistent virus that causes adult T cell leuke-
 
mia and tropical spastic paraparesis/HTLV-I–associated myelopathy. Studies on rabbits have shown
that viral proteins encoded by the open reading frames pX-I and pX-II are required for the es-
tablishment of the persistent infection. To examine the in vivo production of these proteins in
humans, we have investigated whether cytotoxic T lymphocytes isolated from HTLV-I–infected
individuals recognized pX-I and pX-II peptides. CD8
 
1
 
 T lymphocytes to pX-I and pX-II pep-
tides were detected in HTLV-I–infected individuals, whatever their clinical status, and even in
the absence of any antigenic restimulation. These findings indicate that the HTLV-I pX-I and
pX-II proteins are chronically synthesized in vivo, and are targets of the natural immune re-
sponse to the virus.
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Introduction
 
Human T cell leukemia virus type I (HTLV-I) is the etio-
logical agent responsible for adult T cell leukemia (ATL)
and the tropical spastic paraparesis/HTLV-I–associated my-
elopathy (TSP/HAM). HTLV-I is a complex retrovirus. The
3
 
9
 
 region of its genome (termed pX) encodes distinct regu-
latory proteins in addition to the structural genes common
to most retroviruses. Open reading frames (ORFs) pX-III
and pX-IV encode the posttranscriptional regulator Rex
protein and the viral transactivator Tax protein, respec-
tively, which have been extensively studied (1). In contrast,
ORFs pX-I and pX-II encode proteins whose functions in
the viral cycle have not yet been elucidated. These proteins
are each produced from single- and double-spliced tran-
scripts (2). The double-spliced pX-I and pX-II transcripts
encode the Rof and Tof proteins, respectively, whereas the
single-spliced pX-I and pX-II RNAs encode the p12
 
I 
 
pro-
tein consisting of the last 98 residues of Rof, and the p13
 
II
 
protein corresponding to the last 87 residues of Tof, respec-
tively (see Fig. 1 A). After transfection, both the Tof and
p13
 
II
 
 proteins are produced from their respective pX-II
cDNAs, whereas only the p12
 
I
 
 protein is produced from
both the double- and single-spliced pX-I RNAs (2).
Neither pX-I nor pX-II protein is required for virus rep-
lication in vitro (3). However, both are important in vivo,
since the HTLV-I p12
 
I
 
 protein and the Tof protein of
HTLV-II are required for the establishment of a persistent
infection in rabbits (4, 5). HTLV-I p12
 
I
 
 and Tof proteins
probably play a similarly critical role in human infection,
but their production in HTLV-I–infected individuals re-
mains to be proven.
Proteins encoded by pX-I and pX-II ORFs are not, or
are very poorly, recognized by sera from HTLV-I–infected
individuals (6). Therefore, to examine the in vivo produc-
tion of these proteins, we have investigated whether they
are targets of the cytotoxic T cell response generated dur-
ing HTLV-I infection. We established cytotoxic T cell lines
from HLA-A2 HTLV-I–infected individuals with various
clinical status, and studied their ability to recognize pX-I
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and pX-II peptides. We also examined whether CD8
 
1
 
 ef-
fectors directed to pX-I and pX-II peptides were chroni-
cally generated during HTLV-I infection.
 
Materials and Methods
 
Subjects.
 
HTLV-I–infected patients and control donors were
selected on the basis of HLA-A2 molecule expression. All patients
gave their informed consent. Blood samples were collected from
five HTLV-I–positive asymptomatic carriers (41948, 44669, 34522,
15610, and 34672) and three TSP/HAM patients (COU, MAD,
and GUI), originating from the French West Indies, and from
one ATL patient (ED) originating from French Guyana. HTLV-I
seropositivity was verified by the presence of anti–HTLV-I anti-
bodies by ELISA and by Western blot.
HTLV-I–uninfected donors 45542 and 34345 were recruited
in the French West Indies, and uninfected donors 821, 72, and
817 in metropolitan France.
 
Peptides.
 
The HLA-A2–restricted CTL epitopes, peptide 27–35
of the melanoma-associated protein Mart-1 (7; provided by F.
Faure, Institut National de la Santé et de la Recherche Médicale,
U520, Institut Curie, Paris) and peptide 77–85 of the HIV-GAG
protein (8; donated by F. Lemonnier, Institut Pasteur, Paris),
were used as negative controls. The 9-mer pX-I and pX-II pep-
tides used in this study (located downstream of the regions shared
with Rex and Tax, as shown in Fig. 1, B and C) have been de-
scribed previously (9). Tax, pX-I, and pX-II peptides were syn-
thesized with the PepSet synthesis system (Chiron Mimotopes),
suspended in water at 2 mM, and stored at 
 
2
 
20
 
8
 
C.
 
Cell Lines.
 
B lymphoblastoid cell lines (B cell lines) were es-
tablished by immortalizing peripheral B lymphocytes with EBV.
Polyclonal CTL lines were obtained from unfrozen PBMCs, and
cultured for 3 d in RPMI medium supplemented with 5% FCS and
5% human serum (Sigma Chemical Co.). CD8
 
1
 
 T cells were then
isolated by positive selection using anti-CD8–coated magnetic mi-
crobeads (MACS reagent; Tebu), suspended in 2 ml culture me-
dium, and stimulated with 1 
 
m
 
g/ml phytohemagglutinin (PHA-M;
Sigma Chemical Co.) plus 50 U/ml IL-2 (Roussel Uclaf).
 
Chromium-Release Cytotoxic Assay.
 
5 
 
3 
 
10
 
5
 
 cells from the dif-
ferent B cell lines were incubated with 100 
 
m
 
Ci 
 
51
 
Cr (NEN) in
100 
 
m
 
l culture medium, with or without peptides (5 
 
m
 
M), for 1 h
at 37
 
8
 
C, washed twice with culture medium, and plated in dupli-
cate in a 96-well (round-bottomed) culture plate (2,000 cells per
well in 100 
 
m
 
l of culture medium). CD8
 
1
 
 T cells were then
added into 100 
 
m
 
l culture medium at an E/T ratio of 40:1, and
the plates were incubated at 37
 
8
 
C for 5 h. In some cases, anti-
HLA class I antibody (W6/32, 20 
 
m
 
g/ml; Sigma Chemical Co.)
and anti-HLA class II antibody (TU-36, 20 
 
m
 
g/ml; Tebu) were
added to the culture medium for the 5-h period. Aliquots (100 
 
m
 
l)
of supernatant were collected, and the radioactivity, correspond-
ing to released chromium, was counted in a gamma counter
(Amersham Pharmacia Biotech).
 
ELISPOT Assay.
 
Nitrocellulose plates (96-well; Millipore)
were coated with 50 
 
m
 
l anti–human IFN-
 
g
 
 mAb (2 
 
m
 
g/ml; Gen-
zyme Corp.) in carbonate buffer (15 mM NaHCO
 
3
 
, 33 mM
Na
 
2
 
CO
 
3
 
, pH 9.5) for 16 h at 4
 
8
 
C. The wells were washed twice
with culture medium and incubated with 200 
 
m
 
l of the same me-
dium for 2 h at 37
 
8
 
C. Purified CD8
 
1
 
 T lymphocytes were then
plated in triplicate at 5 
 
3 
 
10
 
4
 
/well, and peptides (5 
 
m
 
M) were
added in a total volume of 200 
 
m
 
l. As a positive control, 500
CD8
 
1
 
 cells were also activated with phorbol ester (PMA, 50 ng/ml;
Sigma Chemical Co.) and ionomycin (500 ng/ml; Sigma Chem-
ical Co.). The plates were incubated for 24 h at 37
 
8
 
C, then
 
washed six times with PBS containing 0.05% Tween 20 (PBS-
Tween). Polyclonal rabbit anti–human IFN-
 
g
 
 (100 
 
m
 
l of a 1:250
dilution in PBS-Tween containing 1% BSA; Genzyme Corp.)
was added to each well, and the plates were incubated at 4
 
8
 
C
overnight. They were washed six times with PBS-Tween, and
biotin-conjugated anti–rabbit F(ab
 
9
 
)
 
2
 
 fragment (100 
 
m
 
l of a 1:500
dilution in PBS-Tween-BSA; Boehringer Mannheim) was added
to each well. The plates were incubated for 1 h at 37
 
8
 
C, washed
six times, and incubated with alkaline phosphatase–conjugated
streptavidin (100 
 
m
 
l of a 1:6,000 dilution in PBS-Tween-BSA;
Sigma Chemical Co.) for 1 h at 37
 
8
 
C. Plates were washed six
times, 100 
 
m
 
l alkaline phosphatase substrate (Bio-Rad) was added
to each well, and the plates were then incubated for 1–2 h. Fi-
nally, the plates were washed in water and air-dried, and the col-
ored spots were counted under a stereomicroscope.
 
Results
 
Recognition of
 
 
 
pX-I and pX-II Peptides by CTLs Expanded
from HLA-A2 TSP/HAM Patients.
 
We showed previously
that one peptide located in the pX-I protein (Rof 57–65;
Fig. 1 B) and another in the pX-II protein (Tof 156–164;
Fig. 1 C) were able to associate to HLA-A2 molecules in
vitro
 
 
 
(9). We have now examined whether CTLs directed
Figure 1. Diagram showing the HTLV-I genome and the locations of the
pX-I and pX-II peptides. (A) The structural (top) and regulatory (bottom)
genes of HTLV-I. The coding sequences of the truncated proteins p12I and
p13II are shaded. (B) The pX-I peptides in the amino acid sequences of Rof
and p12I proteins. The Rof and p12I initiator codons are indicated by ar-
rows, and the residues shared by the Rex and Rof proteins are dotted. (C)
The pX-II peptides in the amino acid sequences of the Tof and p13II pro-
teins. The Tof and p13II initiator codons are indicated by arrows, and the
first residue shared by the Tax and Tof proteins is dotted. 
569
 
Pique et al. Brief Definitive Report
 
against these peptides were detected in HLA-A2 HTLV-I–
infected individuals.
We first tested samples from TSP/HAM patients known
to have a greater CTL response to HTLV-I than asymp-
tomatic carriers (10). We also cultivated PBMCs for 3 d
before expansion, to allow restimulation of anti–HTLV-I
CD8
 
1
 
 T lymphocytes by autologous CD4
 
1
 
 infected T
cells, and so maximize the frequency of antiviral CTLs. The
cytotoxic activities of polyclonal CD8
 
1
 
 lines were then
tested against peptide-loaded HLA-A2–autologous B cell
lines after 10–15 d in culture.
There was no cell lysis when CTL lines from the TSP/
HAM patients were incubated with autologous target cells
with no peptide, or pulsed with the control HLA-A2–
restricted CTL epitopes Mart-1 27–35 or HIV-GAG 77–
85 (
 
,
 
5% cell lysis; Fig. 2 A). In contrast, each CTL line lysed
target cells pulsed with the 11–19 peptide (48–82% cell
lysis) located in the Tax protein, which is the immuno-
dominant target of the anti–HTLV-I CTL response (11).
CTL lines from the TSP/HAM patients also lysed target
cells pulsed with the Rof 57–65 peptide (14–23% cell lysis)
or with the Tof 156–164 peptide (22–34% cell lysis) (Fig. 2
A). The Tof 156–164 peptide caused cell lysis up to a con-
centration of 100 nM, whereas recognition of the Rof 57–
65 peptide required higher concentrations (Fig. 2 B), which
is consistent with the relative capacities of these peptides to
associate with HLA-A2 molecules in vitro (moderate and
low binder peptides, respectively; reference 9). The recog-
nition of the Rof 57–65 and Tof 156–164 peptides was in-
hibited by adding anti-HLA class I, but not anti-HLA class
II, antibodies (Fig. 2 C). Finally, target cell lysis was ob-
served when the peptides were loaded on various HLA-
A2–matched target cells, but not on non–HLA-A2 cells
(data not shown). The generation of CTLs to pX-I and
pX-II peptides was not a characteristic of TSP/HAM pa-
tients, since the Rof 57–65 and Tof 156–164 peptides were
also recognized by CTL lines established from three HLA-
A2–asymptomatic carriers (41948, 44669, and 34672) and
one HLA-A2 ATL patient (ED) (Rof 57–65, 12–32% cell
lysis; and Tof 156–164, 12–38% cell lysis; Fig. 2 D). In
contrast, there was no antipeptide CTL activity in three
CTL lines from HLA-A2–uninfected donors (Fig. 2 E). That
CTLs to pX-I and pX-II peptides were generated in
HTLV-I–infected individuals, whatever their clinical status,
and not in uninfected donors, strongly suggests that the
corresponding proteins are produced in vivo and that this
production is a common feature of HTLV-I infection.
 
CTLs from HTLV-I–infected Patients Recognized Peptides
within the Full-Length Rof and Tof Proteins.
 
We next tested
whether CTLs from HTLV-I–infected patients recognized
peptides produced only from the full-length pX-I and pX-II
proteins to determine whether the complete Rof and
Tof proteins were synthesized in vivo. We used the Rof
31–39 peptide (Fig. 1 B) previously shown by us to bind
moderately to HLA-A2 molecules (9). We also used the
Rof 38–46 and Tof 31–39 peptides (Fig. 1, B and C) previ-
ously considered by us to be HLA-A2–nonbinder peptides
because they associated with HLA-A2 molecules only at
high concentrations (our unpublished results). Since exam-
ples of peptides that associate weakly with HLA molecules
in vitro but are potent CTL epitopes have been reported
(12), these peptides were tested despite their poor binding.
CTL lines from two HLA-A2 TSP/HAM patients and two
HLA-A2 HTLV-I carriers recognized the Rof 31–39 pep-
tide (13–27% cell lysis), the Rof 38–46 peptide (23–53%
cell lysis), and the Tof 31–39 peptide (32–39% cell lysis),
whereas there was no activity in two HLA-A2–uninfected
donors (
 
,
 
2% cell lysis) (Fig. 2 F). As for the Rof 31–39 and
Tof 156–164 peptides, the Rof 31–39, Rof 38–46, and Tof
31–39 peptides were only presented by HLA-A2 target
cells, and their recognition was inhibited by anti-HLA class I
antibodies (data not shown). Hence, we identified HLA-
A2–restricted CTL epitopes produced only from the full-
length Rof and Tof proteins. This indicates that the Rof
protein, although not detected in vitro, is well synthesized
Figure 2. Cytotoxic activity of polyclonal CTL lines detected in the
chromium-release assay. (A) Reactivity of CTL lines established from
HLA-A2 TSP/HAM patients against Tax, pX-I, pX-II, and control
HLA-A2–restricted CTL epitopes. (B) Determination of the concentra-
tions of Rof 57–65 and Tof 156–164 peptides required for recognition by
the CTL line from a TSP/HAM patient. (C) Effect of anti-HLA class I
and class II antibodies on recognition of the Rof 57–65 and Tof 156–164
peptides by the CTL line from a TSP/HAM patient. (D) Reactivity of
CTL lines established from HLA-A2 HTLV-I carriers and one ATL pa-
tient (ED) or (E) HLA-A2–uninfected controls, against Tax, pX-I, pX-II,
and control peptides. (F) Reactivity of CTL lines established from HLA-A2
TSP/HAM patients, HLA-A2–infected carriers, and HLA-A2–uninfected
controls against Rof and Tof peptides. *Peptides not tested. 
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in vivo, and that the Tof protein, detected in vitro, is also
produced in vivo.
 
In Vivo–primed CTLs against pX-I and pX-II Peptides Are
Present in HLA-A2 HTLV-I Carriers.
 
Finally, we determined
whether CD8
 
1
 
 
 
effectors directed against Rof and Tof pep-
tides were detected without any restimulation of CD8
 
1
 
 T
lymphocytes by viral products. Since immune effectors are
short-lived cells (13), such a result would imply that some
CD8
 
1
 
 T lymphocytes had been primed in vivo from Rof
and Tof proteins in current production.
We first tried to detect an ex vivo anti–HTLV-I cyto-
toxic activity using the chromium-release assay and found
no response to the Rof and Tof peptides, even though there
was a slight response to the Tax 11–19 peptide (data not
shown). We next used the IFN-
 
g
 
 enzyme-linked immu-
nospot (ELISPOT) assay (14), which is much more sensitive
than the chromium-release assay, to increase the proba-
bility of detecting ex vivo activity to HTLV-I peptides. Since
it has been shown that CD4
 
1
 
 T lymphocytes from TSP/
HAM patients secrete high levels of IFN-
 
g
 
 (15), we used
purified CD8
 
1
 
 T lymphocytes instead of PBMCs. However,
there were many spots in the absence of peptide stimula-
tion, even with purified CD8
 
1
 
 T lymphocytes from TSP/
HAM blood samples (data not shown), which rendered the
interpretation of the results difficult. Assuming that this
background was due to the general immune activation
characteristic of TSP/HAM patients (16), we repeated this
experiment using samples from HTLV-I carriers. Table I
shows the results obtained with freshly purified CD8
 
1
 
 T
cells from three HLA-A2 HTLV-I carriers and three HLA-
A2–uninfected donors as negative controls. No responses
against Tax, pX-I, pX-II, or control peptides were detected
in samples from uninfected donors (
 
,
 
60 spots per 10
 
6
 
 CD8
 
1
 
cells), although they produced large amounts of IFN-
 
g
 
 in
response to mitogens. In contrast, there were many spots
(200–2,180) in samples from the three HTLV-I carriers in
response to the immunodominant Tax 11–19 peptide.
Two HTLV-I carriers (34522 and 15610) also responded to
the Tof 31–39 peptide (660 and 340 spots, respectively) and
to the Tof 156–164 peptide (360 and 260 spots, respec-
tively). All of the HTLV-I carriers recognized peptides from
the Rof protein, since the Rof 38–46 peptide was recog-
nized by two carriers (15610 and 34522; 180 and 500 spots,
respectively), and the Rof 31–39 peptide was recognized by
the third (34672, 140 spots). Finally, none of the CD8
 
1
 
 pop-
ulation isolated from the HTLV-I carriers responded to the
control HLA-A2–restricted CTL epitopes (
 
,
 
80 spots).
The presence of circulating CD8
 
1
 
 effectors against Rof
peptides in blood samples from the three HTLV-I carriers
strongly suggests that the full-length Rof protein is chroni-
cally produced in vivo. That two out of three samples from
HTLV-I carriers respond to the Tof peptides also suggests
that the Tof protein is constantly synthesized during HTLV-I
infection.
 
Discussion
 
We have found that HLA-A2–restricted CTLs against
HTLV-I pX-I and pX-II peptides are present in HTLV-
I–infected individuals, regardless of their clinical status,
while no such activity was present in HLA-matched unin-
fected controls. We have also demonstrated that some of
these effectors have been primed by pX-I and pX-II pep-
tides that are constantly produced in vivo. Finally, we have
identified three HLA-A2–restricted epitopes in the pX-I
ORF (Rof 31–38, Rof 38–46, and Rof 57–65) and two in
 
Table I. Detection of In Vivo–primed IFN-g–producing CD81 Effectors Directed to Tax, Rof, and Tof Peptides in HLA-A2 
HTLV-I–infected Asymptomatic Carriers
HTLV-I–infected carriers Uninfected donors
15610 34672 34522 Positivity
Mean
frequency* 45542 34345 821 Positivity
Mean
frequency
Mitogen 46,000 112,000 134,000 3/3 1/10 66,000 40,000 40,000 3/3 1/20
Control peptides
Mart-1 27–35 0 80 220 0/3 1/50,000 17 60 20 0/3 1/33,000
HIV-GAG 77–85 20 0 NT 0/2 1/100,000 NT 20 20 0/2 1/50,000
HTLV-I peptides
Tax 11–19 500 200 2,180 3/3 1/1,000 17 40 0 0/3 1/50,000
Rof 31–39 0 140 80 1/3 1/14,000 17 40 0 0/3 1/50,000
Rof 38–46 180 60 500 2/3 1/4,000 0 40 0 0/3 1/75,000
Tof 31–39 340 0 660 2/3 1/3,000 0 40 240 0/3 0
Tof 156–164 260 80 360 2/3 1/4,000 0 40 0 0/3 1/75,000
Data shown are the number of IFN-g–producing cells per 106 fresh CD81 T lymphocytes, and are means of triplicates of a representative experiment
out of two. The values represent the number of spots after subtraction of the background observed in the absence of peptide. Peptides inducing a
production of IFN-g corresponding to .100 spots/106 CD81 T lymphocytes were considered as positive. NT, not tested.
*Calculated by dividing 106 by the mean number of spots.571 Pique et al. Brief Definitive Report
the pX-II ORF (Tof 31–39 and Tof 156–164), some of
which are located in the complete Rof and Tof proteins.
Since it seems very unlikely that these peptides are synthe-
sized without the translation of their respective ORFs, our
results strongly suggest that the Rof and Tof proteins are
both chronically produced during HTLV-I infection.
The CTL response to the Tof 156–164, Rof 31–38, and
Rof 57–65 peptides is in good agreement with our previ-
ous finding that these peptides bind to HLA-A2 molecules
in vitro (9). We also found that the Rof 38–46 and the Tof
31–39 peptides act as HLA-A2–restricted epitopes, although
they were not previously considered as HLA-A2 binders.
Nevertheless, these two peptides can stimulate CD81 T
lymphocytes from HTLV-I–infected donors to kill HLA-A2
target cells and to produce IFN-g, and their recognition
was inhibited by anti-HLA class I antibodies. Therefore,
our results confirm that there are some notable exceptions
to the general rule that a direct relationship exists between
the affinity of peptides for HLA molecules in vitro and
their abilities to act as CTL epitopes in vivo, as reported
previously by others (12).
The production of pX-I and pX-II proteins in all HTLV-
I–infected individuals is consistent with their roles in the
establishment of persistent infection in vivo. Our results
suggesting that the pX-I proteins are chronically produced
in vivo, at least in HTLV-I carriers, may also imply that
their functions are required throughout the viral infection.
It has been recently reported that the pX-I p12I protein can
associate with MHC class I molecules and cause their intra-
cellular degradation, which may prevent antigenic presen-
tation of viral proteins by infected cells (17). Constant pro-
duction of the p12I protein in vivo would ensure their
escape from the immune cytotoxic response.
The Rof and Tof proteins are not, or are very poorly,
recognized by sera from HTLV-I–infected individuals (2).
Hence, it seems that these proteins cannot induce an anti-
body response. This inability could be due to their location
in intracellular compartments preventing them from being
exposed to the extracellular environment. However, the
identification of CTL epitopes in the Rof and Tof proteins
demonstrates that these proteins are available for the MHC
class I presentation pathway, and that they are targets of the
natural anti–HTLV-I immune response.
Indeed, we found that CTLs directed against Rof and
Tof peptides are present in TSP/HAM patients and in asymp-
tomatic carriers. Moreover, the result obtained with pa-
tient ED suggests that ATL patients also generate anti-Rof
and anti-Tof CTLs. Therefore, our results indicate that the
antiviral CTL response is diversified toward several regula-
tory proteins, not only to the Tax protein, in all HTLV-I–
infected individuals. That anti-Rof and anti-Tof CTLs were
generated in one ATL donor is especially interesting since
viral expression is believed to be very low in these patients.
Nevertheless, our results suggest that sufficient levels of the
Rof and Tof proteins are produced in leukemic patients to
be targeted by the immune response.
The frequencies of in vivo–primed CD81 effectors
against Rof 38–46, Tof 31–39, and Tof 156–164 peptides
were between 1/4,000 and 1/3,000. These frequencies are
in the same range as those obtained in HIV-1–positive indi-
viduals after stimulation with relevant peptides (14). The fre-
quency of effectors against the Tax 11–19 peptide (1/1,000)
was much lower than those previously reported in TSP/
HAM patients using HLA-A2/Tax 11–19 tetramers (up to
10% PBMCs; reference 18). This difference is not surprising,
since only in vivo–primed cytotoxic effectors were detected
under our conditions, while tetramers detect all anti-Tax
11–19 CTLs, and since carriers had a lower anti-Tax CTL
response than TSP/HAM patients (10). Therefore, our re-
sults confirm that HTLV-I carriers have in vivo–primed
CD81 effectors to Tax (19), and demonstrate that they also
possess in vivo–preactivated effectors to Rof and Tof pep-
tides. We could not assess the frequency of in vivo–primed
anti-Rof and anti-Tof CD81 effectors in samples from TSP/
HAM patients because they produced a high basal amount of
IFN-g. Therefore, it remains to be determined whether the
intensity of the anti-Rof and anti-Tof cytotoxic response
plays a role in the pathogenesis of the TSP/HAM disease.
However, despite minimization by the high background, a
response to the Tax 11–19 peptide was detectable in these
patients (data not shown), which confirms that they chroni-
cally generated IFN-g–producing CD81 lymphocytes to the
Tax protein, as reported recently by others (20).
This study establishes that CTLs against Rof and Tof
proteins are generated during HTLV-I infection. The next
question is whether these CTLs can kill HTLV-I–infected
cells. This point could not be addressed in this study since it
requires the production of CTL lines or clones specific for
each Rof and Tof peptide. Therefore, further experiments
are needed to determine whether the cytotoxic response to
Rof and Tof proteins could destroy infected cells in vivo
and hence, play a role in the control of the HTLV-I infec-
tion. Nevertheless, the immunological approach presented
here provided evidence for the in vivo chronic production
of the HTLV-I Rof and Tof proteins. This approach could
be extended to other persistent infections in which viral
products are, as in HTLV-I infection, physically undetectable.
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